Which has higher valuation & earnings, ARCT or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Arcturus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcturus Therapeutics $82.03M 5.55 -$65.78M -$3.31 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media favor ARCT or TLSA?

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 5 articles in the media. Tiziana Life Sciences' average media sentiment score of 0.38 beat Arcturus Therapeutics' score of 0.37 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TLSA or PRTA?

Prothena has a consensus price target of $24.57, indicating a potential upside of 186.38%. Given Prothena's stronger consensus rating and higher probable upside, analysts clearly believe Prothena is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Prothena 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has better valuation and earnings, TLSA or PRTA?

Tiziana Life Sciences has higher earnings, but lower revenue than Prothena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Prothena $9.68M 46.40 -$244.09M -$0.84 N/A

Does the media refer more to TLSA or PRTA?

In the previous week, Tiziana Life Sciences had 4 more articles in the media than Prothena. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 1 mentions for Prothena. Prothena's average media sentiment score of 1.08 beat Tiziana Life Sciences' score of 0.38 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TLSA or KYTX?

Kyverna Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 320.76%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has higher valuation & earnings, TLSA or KYTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A

Is TLSA or KYTX more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Kyverna Therapeutics N/A -81.92% -63.74%

Does the media refer more to TLSA or KYTX?

In the previous week, Tiziana Life Sciences had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 1 mentions for Kyverna Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.38 beat Kyverna Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TLSA or ZURA?

Zura Bio has a consensus target price of $17.00, indicating a potential upside of 281.17%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zura Bio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has preferable valuation and earnings, TLSA or ZURA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Zura Bio N/A N/A -$99.35M -$1.13 N/A

Is TLSA or ZURA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Zura Bio N/A -56.13% -50.15%

Does the media refer more to TLSA or ZURA?

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 2 mentions for Zura Bio. Tiziana Life Sciences' average media sentiment score of 0.38 beat Zura Bio's score of -0.48 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TLSA or CABA?

Cabaletta Bio has a consensus price target of $15.33, indicating a potential upside of 501.31%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger earnings & valuation, TLSA or CABA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is TLSA or CABA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Cabaletta Bio N/A -128.27% -95.47%

Does the media favor TLSA or CABA?

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.56 beat Tiziana Life Sciences' score of 0.38 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cabaletta Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tiziana Life Sciences (TLSA) Competitors

$0.91 -0.06 (-6.64%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.90 0.00 (-0.07%)

As of 09/18/2026 07:40 PM Eastern

Compare

TLSA vs. ARCT, PRTA, KYTX, ZURA, and CABA

Should you buy Tiziana Life Sciences stock or one of its competitors? Tiziana Life Sciences's main competitors and comparable companies include Arcturus Therapeutics (ARCT), Prothena (PRTA), Kyverna Therapeutics (KYTX), Zura Bio (ZURA), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tiziana Life Sciences compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Tiziana Life Sciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Tiziana Life Sciences' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 5 articles in the media. Tiziana Life Sciences' average media sentiment score of 0.38 beat Arcturus Therapeutics' score of 0.37 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcturus Therapeutics has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Tiziana Life Sciences has lower revenue, but higher earnings than Arcturus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	5.55	-$65.78M	-$3.31	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arcturus Therapeutics presently has a consensus target price of $23.00, indicating a potential upside of 43.48%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Arcturus Therapeutics beats Tiziana Life Sciences on 7 of the 13 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Prothena?

Tiziana Life Sciences (NASDAQ:TLSA) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Prothena has a consensus price target of $24.57, indicating a potential upside of 186.38%. Given Prothena's stronger consensus rating and higher probable upside, analysts clearly believe Prothena is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

97.1% of Prothena shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tiziana Life Sciences has higher earnings, but lower revenue than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Prothena	$9.68M	46.40	-$244.09M	-$0.84	N/A

Tiziana Life Sciences has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Tiziana Life Sciences' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Prothena	-80.68%	-16.45%	-14.51%

In the previous week, Tiziana Life Sciences had 4 more articles in the media than Prothena. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 1 mentions for Prothena. Prothena's average media sentiment score of 1.08 beat Tiziana Life Sciences' score of 0.38 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tiziana Life Sciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Prothena has a beta of -0.33, suggesting that its stock price is 133% less volatile than the broader market.

Summary

Tiziana Life Sciences and Prothena tied by winning 7 of the 14 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Kyverna Therapeutics?

Tiziana Life Sciences (NASDAQ:TLSA) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Tiziana Life Sciences has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Kyverna Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 320.76%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Tiziana Life Sciences' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Kyverna Therapeutics	N/A	-81.92%	-63.74%

In the previous week, Tiziana Life Sciences had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 1 mentions for Kyverna Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.38 beat Kyverna Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

18.1% of Kyverna Therapeutics shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Summary

Tiziana Life Sciences beats Kyverna Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Zura Bio?

Tiziana Life Sciences (NASDAQ:TLSA) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Zura Bio has a consensus target price of $17.00, indicating a potential upside of 281.17%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tiziana Life Sciences has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 2 mentions for Zura Bio. Tiziana Life Sciences' average media sentiment score of 0.38 beat Zura Bio's score of -0.48 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.1% of Zura Bio shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tiziana Life Sciences' return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Zura Bio	N/A	-56.13%	-50.15%

Summary

Tiziana Life Sciences beats Zura Bio on 7 of the 12 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Cabaletta Bio?

Tiziana Life Sciences (NASDAQ:TLSA) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 5 mentions for Tiziana Life Sciences and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.56 beat Tiziana Life Sciences' score of 0.38 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tiziana Life Sciences' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Cabaletta Bio	N/A	-128.27%	-95.47%

Tiziana Life Sciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, meaning that its stock price is 227% more volatile than the broader market.

Cabaletta Bio has a consensus price target of $15.33, indicating a potential upside of 501.31%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Summary

Cabaletta Bio beats Tiziana Life Sciences on 6 of the 10 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSA vs. The Competition

Export

Metric	Tiziana Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$115.25M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	N/A	14.23	275.49	25.40
Price / Sales	N/A	1,440.84	644.44	86.30
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	N/A	15.45	10.46	6.33
Net Income	-$18.43M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-5.67%	-1.21%	0.59%	1.12%
1 Month Performance	-19.14%	-3.29%	-1.74%	-2.39%
1 Year Performance	-50.24%	37.74%	18.13%	5.35%

Tiziana Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSA Tiziana Life Sciences	1.5467 of 5 stars	$0.91 -6.6%	N/A	-50.2%	$115.25M	N/A	N/A	10	News Coverage
ARCT Arcturus Therapeutics	2.9243 of 5 stars	$16.26 -4.0%	$23.00 +41.5%	-21.7%	$462.08M	$82.03M	N/A	111	News Coverage
PRTA Prothena	3.1909 of 5 stars	$8.45 -0.2%	$24.57 +190.9%	+6.3%	$443.04M	$9.68M	N/A	67	News Coverage Positive News
KYTX Kyverna Therapeutics	1.4458 of 5 stars	$7.07 +0.4%	$30.00 +324.3%	+22.9%	$437.23M	N/A	N/A	149
ZURA Zura Bio	2.7689 of 5 stars	$4.51 -1.4%	$17.00 +277.4%	+124.1%	$431.71M	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSA) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. ARCT, PRTA, KYTX, ZURA, and CABA

How does Tiziana Life Sciences compare to Arcturus Therapeutics?

Summary

How does Tiziana Life Sciences compare to Prothena?

Summary

How does Tiziana Life Sciences compare to Kyverna Therapeutics?

Summary

How does Tiziana Life Sciences compare to Zura Bio?

Summary

How does Tiziana Life Sciences compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. ARCT, PRTA, KYTX, ZURA, and CABA

How does Tiziana Life Sciences compare to Arcturus Therapeutics?

Is ARCT or TLSA more profitable?

Does the media favor ARCT or TLSA?

Which has more risk & volatility, ARCT or TLSA?

Which has higher valuation & earnings, ARCT or TLSA?

Do insiders and institutionals have more ownership in ARCT or TLSA?

Do analysts recommend ARCT or TLSA?

Summary

How does Tiziana Life Sciences compare to Prothena?

Do analysts prefer TLSA or PRTA?

Do insiders & institutionals believe in TLSA or PRTA?

Which has better valuation and earnings, TLSA or PRTA?

Is TLSA or PRTA more profitable?

Does the media refer more to TLSA or PRTA?

Which has more risk & volatility, TLSA or PRTA?

Summary

How does Tiziana Life Sciences compare to Kyverna Therapeutics?

Which has more risk & volatility, TLSA or KYTX?

Do analysts recommend TLSA or KYTX?

Is TLSA or KYTX more profitable?

Does the media refer more to TLSA or KYTX?

Do insiders and institutionals have more ownership in TLSA or KYTX?

Which has higher valuation & earnings, TLSA or KYTX?

Summary

How does Tiziana Life Sciences compare to Zura Bio?

Which has preferable valuation and earnings, TLSA or ZURA?

Do analysts prefer TLSA or ZURA?

Which has more volatility & risk, TLSA or ZURA?

Does the media refer more to TLSA or ZURA?

Do insiders & institutionals have more ownership in TLSA or ZURA?

Is TLSA or ZURA more profitable?

Summary

How does Tiziana Life Sciences compare to Cabaletta Bio?

Does the media favor TLSA or CABA?

Is TLSA or CABA more profitable?

Which has more risk and volatility, TLSA or CABA?

Do analysts prefer TLSA or CABA?

Which has stronger earnings & valuation, TLSA or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools